Prosecution Insights
Last updated: April 19, 2026
Application No. 18/289,699

Composition in the Form of a Supramolecular Arrangement Including Hydrophilic Molecules Which is Stabilized by Mineral Particles in a Lipid Phase

Non-Final OA §103§112
Filed
Dec 04, 2023
Examiner
JACOBSON, MICHELE LYNN
Art Unit
1793
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Huddle Corp.
OA Round
1 (Non-Final)
25%
Grant Probability
At Risk
1-2
OA Rounds
4y 2m
To Grant
57%
With Interview

Examiner Intelligence

Grants only 25% of cases
25%
Career Allow Rate
86 granted / 342 resolved
-39.9% vs TC avg
Strong +32% interview lift
Without
With
+31.7%
Interview Lift
resolved cases with interview
Typical timeline
4y 2m
Avg Prosecution
53 currently pending
Career history
395
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
47.7%
+7.7% vs TC avg
§102
18.3%
-21.7% vs TC avg
§112
22.8%
-17.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 342 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant's election with traverse of group I, claims 1-9 in the reply filed on 9 December 2025 is acknowledged. The restriction between claims 1-9 and 10-12 is hereby withdrawn because these claims lack patentable distinctness. Claims 10-12 are examined with claims 1-9 herein. The traversal is on the grounds that Senanayake and Gers-Barlag fail to demonstrate that the corresponding special technical feature does not make a contribution over the prior art. While not acquiescing to the impropriety of the restriction requirement, the corresponding special technical feature of the claims does not make a contribution over the prior art as demonstrated by the rejection of claims 1 and 10 below. The requirement is still deemed proper and is therefore made FINAL. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-12 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 1 and 10 recite the phrase “such as” and claims 2, 3 and 6-12 recite the phrase “preferably”. This exemplary language makes it unclear whether the claimed narrower recitation is a limitation and therefore these claims are indefinite. (MPEP 2173.05(d)) Claims 4 and 5 depend from claim 1 and therefore necessarily inherit the deficiencies therein. Appropriate correction is required. Claim 7 recites “wherein the lecithin sheets are smectite sheets”. The phrase “the lecithin sheets” lack proper antecedent basis in the claims. Neither claim 7 nor claim 1, from which claim 7 depends, positively recite “lecithin sheets”. Additionally, lecithin does not form sheets within the context of the invention. For the purpose of examination, smectite sheets will be interpreted to read on claim 7. Appropriate correction is required. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-12 are rejected under 35 U.S.C. 103 as being unpatentable over Herstein USPN 5902591. Regarding claims 1-10, Herstein teaches a lipid emulsion composition comprising (Col. 6, lines 19-34): 1-20% unsaturated triglyceride esters such as oils of castor, safflower, cottonseed, corn, cod liver, palm, sesame and soybean. (Col. 7, lines 42-44,Col. 8, lines 1-3) 0.1 to 20% Water soluble antioxidant comprising ascorbic acid (vitamin C) (Col. 2, lines 53-57) 1-10% Amphiphilic dispersant comprising lecithin (Col. 4, line 66-Col. 5, line 1,39-40) Montmorillonite phyllosilicate organoclay that has been swelled and exfoliated in a ratio to the ascorbic acid of 0.05-0.5:1 (Col. 4, lines 1-30) 30-70% water The proportions of unsaturated lipid, antioxidant, dispersant, phyllosilicate and water disclosed by Herstein overlap or encompass the proportions of these components recited in claims 1, 2 and 8-10. In the case where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990) Given that Herstein recites the same ingredients as claimed by applicant, the emulsion of Herstein would have ingredients disposed as described by the functional language of claims 1 and 10. Therefore, Herstein renders obvious claims 1-10. Regarding claims 11 and 12, It would have been obvious to one of ordinary skill in the art at the time the application was filed to have varied the proportions of hydrophobic and hydrophilic ingredients in Herstein depending on whether an oil in water or water in oil emulsion was desired. The clay of Herstein would be disposed in the lipid phase and the proportions of clay disclosed by Herstein overlap or encompass the proportions recited in claims 11 and 12. In the case where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990) Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michele L Jacobson whose telephone number is (571)272-8905. The examiner can normally be reached Monday through Friday from 10-6. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Emily Le can be reached at (571) 272-0903. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Michele L Jacobson/Primary Examiner, Art Unit 1793
Read full office action

Prosecution Timeline

Dec 04, 2023
Application Filed
Apr 06, 2026
Non-Final Rejection — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600941
METHOD FOR PRODUCING BIOMASS USING HYDROGEN-OXIDIZING BACTERIA
2y 5m to grant Granted Apr 14, 2026
Patent 12588685
Protein Ingredient and Oil Preparation from The Seeds of Macauba Fruit and Method for Preparing Same
2y 5m to grant Granted Mar 31, 2026
Patent 12575593
TEXTURE MODIFIED FOOD PRODUCT
2y 5m to grant Granted Mar 17, 2026
Patent 12543765
Method of making a dairy-free sweetened condensed milk
2y 5m to grant Granted Feb 10, 2026
Patent 12543771
BATTER SHOWERING APPARATUS AND APPLICATION METHOD
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
25%
Grant Probability
57%
With Interview (+31.7%)
4y 2m
Median Time to Grant
Low
PTA Risk
Based on 342 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month